Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Market Cap$11.19B
Close$
$104.50
84.1% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
84.1% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$153.96171.3% upside
Current Fair Value
171.3% upsideUndervalued by 171.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.19 Billion |
|---|---|
| Enterprise Value | $10.59 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.25 |
| Beta | 0.18 |
| Outstanding Shares | 191,440,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 16.97 |
|---|---|
| PEG | 13.64 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 1.83 |
| Enterprise Value to Revenue | 0.01 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime